Kopfbereich
Zum Nutzerprofil
Inhaltsbereich

Berlin Research Lab

The Berlin Research Lab is an initiative by Pfizer in Germany, its goal is to foster innovation and promote cooperation between partner companies. For example, research partners can come from biopharmaceutical or biomedical research backgrounds. Germany’s dynamic biotech sector is one of the important initiators for the pharmaceutical research.

A wide array of project cooperation is conceivable. Ranging from, drug development or new diagnostic procedures. To the development or optimisation of therapeutic offerings.

Of particular interest are partnerships in the following areas:

  • Inflammatory diseases & Immunology
  • Cardiovascular & Metabolic diseases
  • Neuroscience & Pain
  • Cancer disease
  • Rare diseases
  • Vaccines

Institutions and companies, who are interested in research and development in these fields and a partnership with Pfizer can contact us directly. Please use the contact form. We are looking forward to your suggestions and guarantee fast processing of your inquiry.

 

 

BaseLaunch

Pfizer supports BaseLaunch, an initiative of BaselArea.swiss, which works to attract and accelerate promising and groundbreaking healthcare startups and strengthen the Basel region’s position as leading life sciences hub.

The accelerator program provides participating teams with infusions of funds, insight, infrastructure and industry access, and integrates them into one of the most dynamic biotech and pharma ecosystems in Europe. BaseLaunch is supported by Pfizer and other healthcare partners as well as other public and private partners. Applications are vetted by a selection committee consisting of Dr. Fabian Buller, Director New Ventures, Johnson & Johnson Innovation, Dr. Phillipe Dro, CEO, NeMoDevices, Trudi Haemmerli, CEO and Director, PerioC Ltd, Managing Director, TruStep Consulting GmbH, Dr. Anja König, Managing Director, Novartis Venture Fund, Dr. Alex Mayweg, Venture Partner, Versant Ventures and Dr. Nathalie ter Wengel MD, European Head External R&D and Innovation, Pfizer. For more information and to apply for the program, please visit: www.baselaunch.ch.

Es folgt ein Inhalt, der nicht in den Lesefluss gehört:

Interessantes!

Key dates Application Deadline: June 30, 2017 Phase I: Sept 15, 2017 – Dec 7, 2017 Phase II: Jan 2 – Dec 21, 2018

Ende des Inhaltes

Fußbereich